MilligramLab

Probiotics vs Prebiotics: What the Definitions Actually Require

TL;DR: Probiotics are live microorganisms. Prebiotics are substrates those microorganisms feed on. Both definitions come from the same scientific body and both carry conditions that most products on the shelf do not meet. Across 395 on-market US probiotic supplements we examined, 49.9% named no strain for any organism, and of the 151 that also contained a named prebiotic substrate, not one declared enough of it to match the dose ISAPP associates with a prebiotic effect.

Nearly every page on this topic stops at one sentence: probiotics are the bacteria, prebiotics are the food. That is correct and almost useless, because it leaves out the part that decides whether the bottle in your hand is either thing.

Both words have formal consensus definitions, written by the International Scientific Association for Probiotics and Prebiotics (ISAPP) in Nature Reviews Gastroenterology & Hepatology. Both carry conditions. We pulled 395 probiotic products from the NIH Dietary Supplement Label Database to see how many satisfy them.

Quick comparison

Probiotics Prebiotics
What it is Live microorganisms A substrate (usually a non-digestible carbohydrate)
Consensus definition “Live microorganisms that, when administered in adequate amounts, confer a health benefit on the host” (Hill et al. 2014) “A substrate that is selectively utilized by host microorganisms conferring a health benefit” (Gibson et al. 2017)
Common examples Lacticaseibacillus rhamnosus GG, Bifidobacterium animalis subsp. lactis BB-12, Saccharomyces boulardii Inulin, FOS, GOS, lactulose, human milk oligosaccharides
Survives your gut? Must arrive alive, in viable numbers Must not be digested — that is the point
Measured in CFU (colony-forming units) Grams
Dose with evidence behind it Strain-specific; no single number applies 5–8 g/day of FOS or GOS (ISAPP)
On-market US labels using the word 3,741 1,519
Strength of evidence Stronger of the two, per ISAPP Weaker — “the strength of evidence for probiotics exceeds that of prebiotics” (ISAPP)

Each definition is one sentence, and each has conditions

Neither definition mentions strains, doses or CFU counts. The conditions live in the frameworks published alongside them. For probiotics, what a product must prove depends on what it claims. For prebiotics, the substrate must be shown to be selectively used, with the microbiota change and the health benefit appearing in the same study.

The probiotic framework in Hill et al. 2014 is tiered, and the tier matters:

  • “Contains live and active cultures” — any food fermentation microbe, with no product-specific efficacy studies needed. The panel was explicit that such products “should not be called probiotic.”
  • “Contains probiotics”, with no specific health claim — requires a safe species with general-benefit evidence in humans. Critically, “the evidence does not have to be generated for the specific strain included in the product.”
  • A specific health claim — now requires “defined probiotic strain(s)”, “proof of delivery of viable strain(s) at efficacious dose at end of shelf-life”, and convincing evidence for that strain in that indication.

So the widely repeated line that an unlabelled strain disqualifies a product from being a probiotic is not what ISAPP said. Strain identity becomes mandatory at the point a specific claim is made; below that, species-level evidence is permitted.

For prebiotics, the 2017 criteria are stricter than the word “fiber” suggests. ISAPP’s guidance lists when an ingredient is not a prebiotic: when it is degraded before reaching the target site, when it is fermented but not selectively, or “when it is not administered in sufficient amounts to confer a measurable benefit.” Their blunt summary: “Many food ingredients are being touted as prebiotics when in reality they are not.”

In plain terms: “selectively utilized” means the fibre has to feed particular microbes rather than everything living in the gut. A fibre that feeds the whole room is a fibre; a prebiotic has to be shown to feed the organisms the benefit is attributed to.

Synbiotic is the third category, and almost nobody uses the word

A synbiotic is a mixture of live microorganisms and a selectively utilized substrate that together confer a benefit (Swanson et al. 2020). It is a formal ISAPP category alongside probiotic, prebiotic and postbiotic — and it is effectively absent from US labels. We counted 43.

Four ISAPP categories and how often each word appears on US supplement labels Four consensus categories defined by ISAPP. Probiotic, defined in 2014, appears on 3,741 on-market US supplement labels. Prebiotic, defined in 2017, appears on 1,519. Synbiotic, defined in 2020, appears on just 43. Postbiotic, defined in 2021, appears on 26. The two newer categories are roughly 87 and 144 times rarer than probiotic. Four categories, two of which the market has barely noticed On-market US dietary supplement labels matching each term · NIH DSLD, retrieved November 2026 Probiotic Hill et al. 2014 Live microorganisms that, when administered in adequate amounts, confer a health benefit. 3,741 labels Prebiotic Gibson et al. 2017 A substrate that is selectively utilized by host microorganisms conferring a benefit. 1,519 labels Synbiotic Swanson et al. 2020 Live microorganisms plus a selectively utilized substrate, benefiting together. 43 labels — 87x rarer than probiotic Postbiotic Salminen et al. 2021 A preparation of inanimate microorganisms and/or their components conferring a benefit. 26 labels — 144x rarer
Bar lengths are proportional to label counts; the two lower bars are drawn at a 3-pixel minimum so they remain visible. Definitions quoted from the ISAPP consensus statements.

The gap is not because combination products are rare. Of our 395 probiotic products, 151 (38.2%) already contained a named prebiotic substrate — inulin in 132 of them, FOS in most of the rest. Yet “synbiotic” appeared anywhere on only 2 of those 395 records, both from one brand, and in both cases inside the ingredient name “Proprietary Synbiotic Blend.”

That restraint may be appropriate, because the category has a rule most combination products would fail. On the obvious shortcut, the consensus statement is direct: “A product containing a probiotic and a prebiotic that only has evidence for each component individually, and not as a combination product, should not be called a synbiotic.”

What we found on 395 US probiotic labels

We queried the NIH Dietary Supplement Label Database for on-market supplements matching “probiotic”, kept the records containing at least one microbial ingredient, and deduplicated to 395 distinct products from 196 brands. Then we checked how far down the taxonomy each label goes.

Strain-level declaration across 395 US probiotic products Of 395 products, 36.2 percent name a strain designation for every organism listed, 13.9 percent do so for some but not all, and 49.9 percent name none at all. Counting the 2,506 individual organisms listed across those products, only 34.2 percent carry a strain designation; the remaining 65.8 percent are identified by genus and species only, or less. Half of probiotic labels stop at the species name Source: NIH Dietary Supplement Label Database, retrieved November 2026 By product n = 395 products 36.2% 13.9% 49.9% By organism listed n = 2,506 entries 34.2% 65.8% Strain designation given (e.g. “Lactobacillus acidophilus La-14”) Some organisms named to strain, others not Genus and species only, or less
Strain designation was detected as an alphanumeric code following the organism name. Classification was verified by hand against a 25-product sample.

Three findings stood out.

Half of products name no strain at all. 197 of 395 (49.9%) list organisms only as genus and species — “Lactobacillus acidophilus”, “Bifidobacterium longum” — or abbreviated as “L. casei”. Across the 2,506 individual organisms listed, only 857 (34.2%) carry a strain code.

CFU disclosure is thinner than it looks. A CFU figure appeared somewhere in 259 of 395 records (65.6%), but only 59 (14.9%) gave a count for every organism listed — which is what ISAPP recommends. Just 27 (6.8%) did both: named every strain and gave its individual count.

Products are crowded. The median listed 5 organisms and one listed 31, with 70 products (17.7%) landing on exactly 10 — a round number that reads as a marketing target rather than a dosing rationale.

Why the strain code matters more than the CFU number

Strain designation is the unit the research is conducted in. The World Gastroenterology Organisation is explicit: a probiotic strain is identified by genus, species, subspecies where applicable, “and an alphanumeric designation that identifies a specific strain.” Without that code, you cannot look up what was studied. In plain terms: genus and species work like a surname and a first name, and the strain code is the house number. “Lactobacillus acidophilus” names a group of organisms that do not all behave alike; the code is what pins down the one a trial actually used.

The AGA puts the consequence plainly in its announcement of the guideline: “the effects of probiotics are not species-specific, but strain- and combination-specific.” That sentence is in the announcement rather than the guideline paper itself, which is worth knowing if you go looking for it. The NIH Office of Dietary Supplements agrees that because effects “can be specific to certain probiotic strains, recommendations for their use in the clinic need to be strain-specific.”

Naming makes this harder than it sounds. One organism travels under four labels in the WGO’s own table: Lacticaseibacillus rhamnosus GG is deposited as ATCC 53103, nicknamed LGG, sold as Culturelle. And “strain designations, product names, and trade names are not controlled by the scientific community.”

Against that, the CFU number is weaker than it looks, for a reason few pages mention. Per the NIH Office of Dietary Supplements: “Current labeling regulations only require manufacturers to list the total weight of the microorganisms on probiotic products’ Supplement Facts labels; this cellular mass can consist of both live and dead microorganisms.” CFU disclosure is voluntary. ODS adds that “products with higher CFU counts are not necessarily more effective,” and that a count at time of manufacture says nothing about what survives to the expiry date.

Applying both tests in sequence narrows the shelf sharply.

How many of 395 probiotic products survive two label tests A funnel. All 395 probiotic products enter. 198, or 50.1 percent, name a strain designation for at least one organism. 143, or 36.2 percent, name one for every organism listed. 27, or 6.8 percent, do that and also give each organism its own CFU count. The remaining 368 products fail one test or the other. Two label tests, applied in order, leave 27 products standing 395 on-market US probiotic supplements · NIH DSLD, retrieved November 2026 All probiotic products the starting shelf 395 · 100% Name a strain for at least one organism 198 · 50.1% 197 drop out Name a strain for every organism 143 · 36.2% 55 more drop out … and give each organism its own CFU count 27 · 6.8% 116 more drop out Neither test asks whether the strain works. They ask only whether you can look it up and know what dose you received. A per-strain CFU count through the expiry date is what ISAPP advises manufacturers to print.
Sequential filtering of 395 US probiotic products. Shaded bars show the share failing each test; the funnel narrows from 395 to 27.

The prebiotic dose problem

ISAPP associates a dietary prebiotic effect in adults with 5–8 g/day of FOS or GOS. We pulled the full Supplement Facts panel of all 151 of our probiotic products containing a named prebiotic substrate. Not one declared 3 g. The median was 100 mg. In practice: FOS and GOS stand for fructo-oligosaccharides and galacto-oligosaccharides, two of the best-studied prebiotic fibres — and a 5 g dose of either is a powder you stir into a drink, not something that fits inside a capsule alongside bacteria.

Declared prebiotic amounts versus the dose ISAPP associates with an effect On a logarithmic milligram scale, the 58 products that declared a weight for their prebiotic substrate span 5 milligrams to 2 grams, with a median of 100 milligrams. ISAPP associates a dietary prebiotic effect with 5 to 8 grams per day of FOS or GOS. The two ranges do not overlap, and no product reached even 3 grams. A further 93 products declared no weight at all. The prebiotic in a probiotic capsule is a gesture, not a dose Declared amount per serving, log scale · NIH DSLD full label panels, retrieved November 2026 1 mg 10 mg 100 mg 1 g 10 g 5–8 g ISAPP 3 g — reached by 0 products 58 products that declared a weight 5 mg 2 g median 100 mg 93 products declared no weight at all — the substrate sat inside a proprietary blend The highest declared amount on any of the 151 labels was 2 g — between a quarter and two fifths of the figure ISAPP cites. A separate prebiotic powder, dosed in grams, is the only format in which these numbers are reachable.
Declared prebiotic substrate per serving against ISAPP's 5–8 g/day reference for FOS or GOS. Substrates counted: inulin, FOS, oligofructose, GOS, chicory root fibre, XOS and IMO.

93 of the 151 (61.6%) gave no weight for the prebiotic at all, because it sat inside a proprietary blend, where only the blend’s combined weight has to be declared and not the amount of each ingredient in it. Of the 58 that did: 23 under 100 mg, 31 between 100 and 499 mg, one between 500 and 999 mg, three between 1 g and 2 g.

Being fair in both directions: ISAPP’s 5–8 g figure is specific to FOS and GOS, and its 2024 classification paper notes effective doses vary by compound and population. A 500 mg inulin dose is not proven inert. But the gap is a factor of 10 to 50, and nothing published closes a gap that size.

Where the evidence stops

Neither category has the evidence base the marketing implies, and ISAPP says so about its own field: “currently the strength of evidence for probiotics exceeds that of prebiotics.” Probiotics have the larger trial literature; prebiotics the clearer mechanism and thinner outcome data.

The most restrictive reading comes from the AGA’s 2020 clinical practice guideline, which applied GRADE methodology — the standard system for rating how certain a body of evidence is — and concluded that “for most digestive conditions there is not enough evidence to support the use of probiotics.” It backs specific formulations in three narrow clinical settings, confines Crohn’s disease, ulcerative colitis, IBS and C. difficile treatment to clinical trials, and recommends against use in children with acute infectious gastroenteritis.

One mechanistic finding explains why group averages behave oddly here. Zmora et al. 2018, sampling the gut lining endoscopically rather than reading stool, found colonisation by an 11-strain probiotic was “person-, region- and strain-specific” — some people resistant, some permissive — and “indistinguishable by probiotics presence in stool.” That does not say probiotics do nothing. It says what is being averaged across trial participants is not the same thing in each participant.

Food, and who should be careful

Fermented foods are not probiotics unless they clear the bar. The 2014 panel was specific: live microbes in fermented foods “fall short of the criteria needed to be considered ‘probiotics’”, and such foods “are best described as ‘containing live and active cultures’”.

Prebiotic substrates do occur in ordinary food — chicory, Jerusalem artichoke, leek, onion, garlic, asparagus, wheat, banana and oat — but ISAPP’s caveat lands where our label data did: “it would take a large quantity of these foods to get a prebiotic effect.”

The clearest documented risk sits with preterm infants. In 2023 the FDA issued a warning about probiotic products given to hospitalised preterm infants, citing one infant death and more than two dozen adverse events since 2018, and noting these products have not gone through FDA premarket review for medical uses. The NIH Office of Dietary Supplements notes evidence that probiotics “may cause harm in certain populations, including people who are severely ill or immunocompromised.” For prebiotics the downside is mundane: ISAPP lists “excessive gas in the gut” among the side effects that disqualify an ingredient at a given dose.

Which one should you choose?

If you want the better-evidenced category: probiotics, on ISAPP’s own assessment — but the evidence attaches to named strains in named conditions, not to the category.

If you want a prebiotic effect: buy the substrate in grams, as a powder. We found no capsule that reaches the referenced dose.

If you are comparing two probiotic bottles: pick the one that names every organism to strain level and gives each a CFU count through the expiry date. Only 6.8% did both, which makes it an unusually effective filter.

If you are immunocompromised, severely ill, pregnant, or considering this for an infant: this is a conversation with a clinician, not a label-reading exercise. See our evidence grading method for how we weigh research.

Frequently asked questions

What is the difference between probiotics and prebiotics?

Probiotics are live microorganisms administered in adequate amounts; prebiotics are substrates that resident microorganisms selectively use. Both definitions require a demonstrated health benefit. Probiotics are dosed in colony-forming units and must arrive alive; prebiotics are dosed in grams and must survive digestion unabsorbed.

Should I take a probiotic, a prebiotic, or both?

No trial has compared the three options against each other in healthy adults, so this cannot be answered from evidence. ISAPP rates the probiotic evidence base as the stronger of the two. A combination only qualifies as a synbiotic if the combination itself has been studied, which almost no retail product can show.

Does a higher CFU count mean a better probiotic?

Not according to the NIH Office of Dietary Supplements, which states that products with higher CFU counts are not necessarily more effective. CFU disclosure is voluntary on US labels; only total microorganism weight is required, and that weight includes dead cells. A count stated at time of manufacture does not tell you what survives to the expiry date.

What is a synbiotic?

A mixture of live microorganisms and a selectively utilized substrate that confers a health benefit, defined by ISAPP in 2020. Complementary synbiotics combine a qualifying probiotic with a qualifying prebiotic; synergistic ones pair a microbe with a substrate chosen for it. We found the word on only 43 on-market US labels.

Why does my probiotic label only say “Lactobacillus acidophilus”?

Because US labels are not required to state the strain, and roughly half do not. Under the ISAPP framework, species-level identification is permitted for a product making no specific health claim. A strain designation becomes mandatory once a specific claim is made — and it is the only way to trace what was studied.

Verdict

Winner
Strength of published evidence Probiotics — on ISAPP’s own assessment
Clarity of mechanism Prebiotics — selective fermentation is better characterised than colonisation
Label transparency on US shelves Neither — 49.9% of probiotic labels name no strain; 61.6% of prebiotic-containing products declare no weight
Dose you can verify from the panel Probiotics, narrowly — 65.6% state a CFU figure somewhere
Dose that matches the referenced evidence Neither in capsule form — no product reached 3 g of prebiotic substrate
Availability from ordinary food Prebiotics — though not in effective quantities
Formal recognition of the combination Synbiotics — defined in 2020, used on 43 labels

Overall: the two are not competitors, which is why “probiotics vs prebiotics” is the wrong frame to shop with. The real split is between products whose contents you can trace to published research and products whose contents you cannot. On that test the 6.8% that name every strain and give each a CFU count sit apart from the rest of the shelf — and the prebiotic inside a probiotic capsule is, across 151 labels, decorative.

Sources

  • Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11:506-14. doi:10.1038/nrgastro.2014.66
  • Gibson GR, Hutkins R, Sanders ME, Prescott SL, Reimer RA, Salminen SJ, et al. Expert consensus document: ISAPP consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol. 2017;14:491-502. doi:10.1038/nrgastro.2017.75
  • Swanson KS, Gibson GR, Hutkins R, Reimer RA, Reid G, et al. The ISAPP consensus statement on the definition and scope of synbiotics. Nat Rev Gastroenterol Hepatol. 2020;17:687-701. PMC7581511
  • Salminen S, Collado MC, Endo A, Hill C, Lebeer S, et al. The ISAPP consensus statement on the definition and scope of postbiotics. Nat Rev Gastroenterol Hepatol. 2021;18:649-67. PMC8387231
  • Hutkins R, Walter J, Gibson GR, Bedu-Ferrari C, Scott K, et al. Classifying compounds as prebiotics — scientific perspectives and recommendations. Nat Rev Gastroenterol Hepatol. 2024. Summarised by ISAPP
  • Su GL, Ko CW, Bercik P, Falck-Ytter Y, Sultan S, et al. AGA clinical practice guidelines on the role of probiotics in the management of gastrointestinal disorders. Gastroenterology. 2020;159(2):697-705. doi:10.1053/j.gastro.2020.05.059 · AGA summary
  • Zmora N, Zilberman-Schapira G, Suez J, Mor U, Dori-Bachash M, et al. Personalized gut mucosal colonization resistance to empiric probiotics is associated with unique host and microbiome features. Cell. 2018;174(6):1388-1405. PMID 30193112
  • Suez J, Zmora N, Zilberman-Schapira G, Mor U, Dori-Bachash M, et al. Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT. Cell. 2018;174(6):1406-1423. PMID 30193113
  • O’Connor LE, Gahche JJ, Herrick KA, Davis CD, Potischman N, Vargas AJ. Nonfood prebiotic, probiotic, and synbiotic use has increased in US adults and children from 1999 to 2018. Gastroenterology. 2021;161(2):476-486. doi:10.1053/j.gastro.2021.04.037
  • NIH Office of Dietary Supplements. Probiotics — Health Professional Fact Sheet.
  • World Gastroenterology Organisation. Global Guideline: Probiotics and Prebiotics, 2023.
  • International Scientific Association for Probiotics and Prebiotics. Prebiotics: A Consumer Guide for Making Smart Choices, 2021; and A roundup of the ISAPP consensus definitions.
  • US Food and Drug Administration. FDA raises concerns about probiotic products sold for use in hospitalized preterm infants, 2023.
  • Reid G, Gadir AA, Dhir R. Probiotics: reiterating what they are and what they are not. Front Microbiol. 2019;10:424. PMC6425910
  • NIH Dietary Supplement Label Database (DSLD) — label data for 395 probiotic products from 196 brands, and full Supplement Facts panels for 151 of them, retrieved November 2026. Term counts taken from on-market label searches on the same date.

Label analysis method: 500 on-market label records matching “probiotic” were retrieved from the DSLD API; 493 contained at least one ingredient classified as bacteria, yeast or fungus; these were deduplicated by brand and product name to 395 distinct products. Strain designation was detected as an alphanumeric code following the organism name and verified by hand against a 25-product sample. Prebiotic amounts were read from the full Supplement Facts panel of every product containing inulin, FOS, oligofructose, GOS, chicory root fibre, XOS or IMO.

This page provides general information and does not replace advice from a qualified healthcare professional. Talk to your doctor or pharmacist before starting a probiotic or prebiotic supplement, particularly if you are immunocompromised, seriously ill, pregnant or breastfeeding, or considering one for an infant.

Information only, not medical advice. Talk to a doctor or pharmacist before starting a supplement, particularly if you have kidney disease, are pregnant or breastfeeding, or take prescription medication.